RCPI Profile
Rock Creek Pharmaceuticals, Inc. (RCPI) is a pharmaceutical company focused on developing and commercializing therapies for chronic inflammatory and neurologic diseases. The company's lead product candidate is Anatabine citrate, an anti-inflammatory compound that has shown potential for the treatment of a range of inflammatory conditions.
Anatabine citrate is a naturally occurring compound found in plants of the Solanaceae family, such as tomatoes, potatoes, and peppers. It has been shown to have anti-inflammatory and immunomodulatory effects in preclinical studies. RCPI has conducted a number of clinical trials to evaluate the safety and efficacy of Anatabine citrate in various indications, including ulcerative colitis, thyroiditis, Alzheimer's disease, and multiple sclerosis.
In addition to Anatabine citrate, RCPI is also developing other drug candidates for the treatment of neurological disorders, including Parkinson's disease and traumatic brain injury.
RCPI was founded in 2013 and is headquartered in Sarasota, Florida. The company is publicly traded on the OTC market under the ticker symbol RCPI.
|
